Alzheimer Disease Clinical Trial
Official title:
A Longitudinal Population Study on Brain Aging and Mental Performances for the 1935-1939 Born People Living in Abbiategrasso (a Small Town Near Milan)
Longitudinal observational study of cognitive functions, physical health and biological
parameters in the whole population living in Abbiategrasso born between 1935 and 1939,1773
subjects, followed for six years in order to know the prevalence and the incidence of
dementia and risk and protective factors of normal and pathological mental aging.
The peculiarities of this study that must assure the outcome efficacy are:
- Selected age: since 70-75 years old people represents a transition age from adulthood
to old age, it is of special interest to study the evolution of psychic and physical
functions of this population
- Whole population not a sample study
- Location: the small area involved (Abbiategrasso is a town of 30.000 inhabitants)can
contribute to guarantee more homogeneity among the subjects and reduce undesired
variability
- multidimensional assessment(biological, clinical, social, psychological data collected)
After initial screening, the recruited population will be followed up for two more
times (every two years )
Background:
Dementia is one of the most troubling neurodegenerative syndrome whose prevalence and
incidence is strongly increasing. The etiology and physiopathology of the process that
causes dementia are still controversial and largely unknown. So it is of paramount
importance to isolate risk and protection factors related to dementia syndrome and Alzheimer
disease. These meager known factors (biological, as well as social and neuropsychological)
can be better investigated through a multidimensional longitudinal study in a homogeneous
population by age and place.
Method:
People belonging to the selected population (1773 subjects living in Abbiategrasso and born
between 1935 - 1939) were invited to participate at a comprehensive assessment which was
divided in two appointments:
- a first appointment (about 1 hour and half) for blood sample, social questionnaire,
anthropometric and walking speed evaluation ;
- a second one (2 hours)for clinical examination and neuropsychological assessment of
mood and cognitive function.
Recruitment. People were recruited through several steps:
- involvement of the family doctor;
- a general call, based on age group(1935,1936, 1937, 1938, 1939), since to be born in
the same year is an identity mark for these generations;
- kick-off meetings for each age class explaining aims and methods of the research,
followed by a party with music, plays and some lotteries
- a letter with the date of the appointment followed by the phone call whenever the phone
number is available
- further letters and call until either a rejection or an appointment was taken.
Assessment. Professionals and instruments:
- Trained interviewers, one social worker and two nurses, administer the social
questionnaire that is partly derived from the CERAD and from other longitudinal
studies.
- Trained psychologists administer a neuropsychological battery exploring mood (GDS 15
items), verbal and visual memory (Rey 15-item Memory Test, and the Rey-Osterrieth
Complex Figure Test (ROCF) recall; Babcock Story Recall Test ), executive function (
TMTA and TMTB; copy of ROCF), attention (Numerical Attention), abstract reasoning
(Raven's Coloured Progressive Matrices), screening cognitive test (Clock test and
MMSE).
- Clinical interview and visit are executed by expert geriatricians, members of the same
geriatric staff who apply diagnostic criteria for dementia (DSM IV), Alzheimer disease
(NINCDS ADRDA diagnostic criteria); Vascular dementia (NINDS -AIREN criteria); Lewy
Body dementia (third report, DLB consortium); frontotemporal dementia ( 2002 modified
Consensus conference criteria). Other cognitive problems were classified as Mild
Cognitive Impairment (MCI) following Petersen's criteria or Cognitive Impairment No
Dementia (CIND) when cognitive impairments are in areas other than memory and they do
not meet whole criteria for dementia. Every diagnostic conclusion is revised by another
doctor; in case of discrepancies a third geriatrician, chief of the study, intervenes
to arbitrate.
All the instruments were pre tested for inter rater reliability in a similar population
attending a geriatric day hospital, and some general agreement sessions were performed
before and during the screening.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |